The focus of this work was to enhance tumor retention of FAP-targeting radiotracers while simultaneously retaining the excellent imaging contrast of FAPI-02 and FAPI-04—that is, to develop an optimized theranostic tracer. The gene discussed is FAP; the disease is neoplasm.